Literature DB >> 1690915

The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis.

J Woo1, H F Sewell, A W Thomson.   

Abstract

The influence of FK-506 and ciclosporin (CsA), either alone or in combination, on PHA- and alloantigen-induced human blood lymphocyte transformation was investigated. The concentrations of FK-506 and CsA required to cause 50% inhibition of mitogen-induced thymidine incorporation were 1.0 and 200 ng/ml respectively. Evidence of synergistic inhibition of DNA synthesis was obtained when doses of each drug below these concentrations were combined (FK-506, less than or equal to 0.5 ng/ml; CsA less than or equal to 50 ng/ml). In contrast, FK-506 and CsA failed to inhibit PHA-induced increases in cell size and granularity determined by flow cytometric analysis at 1 and 3 days of culture. Moreover, no significant changes in the expression of the interleukin 2 receptor (IL-2R; CD25), transferrin receptor (TR; CD71) or HLA-DR were observed in terms of percentage positive lymphocytes or mean cell surface membrane fluorescence intensity. In primary mixed lymphocyte cultures, 50% inhibition of thymidine incorporation was obtained with FK-506 and CsA concentrations of approximately 0.25 and 25 ng/ml respectively. Evidence of synergy was obtained when lower doses of each drug were combined (FK-506, less than or equal to 0.1 ng/ml; CsA less than or equal to 2 ng/ml). On their own, these concentrations of CsA were ineffective. In contrast to corresponding PHA-stimulated cells, FK-506-treated alloactivated lymphocytes exhibited reductions in IL-2R, TR and HLA-DR antigen expression, which in the cases of IL-2R and TR were further reduced by combination of FK-506 with low-concentration CsA. These data provide further evidence of the potential of combined low-dosage FK-506 and CsA for the control of human T-cell activation and proliferation in response to allostimulation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1690915     DOI: 10.1111/j.1365-3083.1990.tb02772.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  9 in total

1.  The influence of FK-506 on the thymus: an immunophenotypic and structural analysis.

Authors:  R G Pugh-Humphreys; C S Ross; A W Thomson
Journal:  Immunology       Date:  1990-07       Impact factor: 7.397

2.  Inhibitory effect of cyclosporin A on T lymphocyte DNA synthesis.

Authors:  M Li; H Zhang; J Yang; J F Shao; H Y Jiang
Journal:  J Tongji Med Univ       Date:  1992

3.  Antigen presentation and HLA-DR expression by FK-506-treated human monocytes.

Authors:  J Woo; D J Propper; A W Thomson
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

4.  Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion.

Authors:  J Woo; D J Propper; A M Macleod; A W Thomson
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

Review 5.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Authors:  D H Peters; A Fitton; G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

6.  Comparison of FK-506 and cyclosporine regimens in pediatric renal transplantation.

Authors:  D Ellis; R Shapiro; M L Jordan; V P Scantlebury; N Gilboa; L Hopp; N Weichler; A G Tzakis; R L Simmons
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

7.  Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial.

Authors:  B Lemster; L L Huang; W Irish; J Woo; P B Carroll; K Abu-Elmagd; H R Rilo; N Johnson; R Russell-Hall; J J Fung
Journal:  Autoimmunity       Date:  1994       Impact factor: 2.815

8.  Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures.

Authors:  A W Thomson; J Woo; G Z Yao; S Todo; T E Starzl; A Zeevi
Journal:  Transpl Immunol       Date:  1993       Impact factor: 1.708

9.  Combination therapy of interferon Beta-1b and tacrolimus: a pilot safety study.

Authors:  F Jacques; I Gaboury; S Christie; F Grand'maison
Journal:  Mult Scler Int       Date:  2012-08-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.